期刊
NEURO-ONCOLOGY
卷 22, 期 4, 页码 450-456出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/noz233
关键词
glioma; adult; recurrence; pathology; pseudoprogression
资金
- NCATS NIH HHS [UL1 TR001422] Funding Source: Medline
- NCI NIH HHS [P50 CA221747] Funding Source: Medline
- NINDS NIH HHS [R01 NS102669] Funding Source: Medline
Regardless of subtype, diffuse gliomas of adulthood are characterized by inexorable progression through treatment. Cancer recurrence in the context of therapy is by no means unique to gliomas. For many tumors residing outside the central nervous system (CNS), tissue-based analyses are routinely employed to document the molecular and cellular features of disease recurrence. Such interventions are inconsistently applied for gliomas, however, and lack rigorous standardization when they are. While many of the reasons underlying these discrepancies reflect pragmatic realities inherent to CNS disease, the suboptimal employment of histological and molecular assessment at recurrence nevertheless represents a missed opportunity to proactively guide patient management and increase knowledge. Herein, we address this quandary by pairing a succinct description of the histological, biological, and molecular characteristics of recurrent glioma with recommendations for how to better standardize and implement quality pathological assessment into patient management. We hope this review will prompt thoughtful revision of standard operating procedures to maximize the utility of glioma re-biopsy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据